Levonorgestrel, Intrauterine Drug Delivery System
Recommended · restricted Women's healthRestricted benefitNot applicable line
Treatment of idiopathic menorrhagia when oral medical therapies for menorrhagia have been ineffective or are contraindicated.
1
Submissions
2007–07
On the record
—
ICER range
Cost-min
Cost basis
Access path
- Mar 2007Recommended · restricted
vs hysterectomy
- PBS listing · Restricted benefit
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis used; no ICER calculated. PBAC noted overall savings of approximately $5,000 per patient over five years for cases where hysterectomy was not undertaken.
The PBAC considered that levonorgestrel IUD has a place in the treatment of menorrhagia and accepted that a number of patients would progress to have a hysterectomy despite its use. PBAC · 2007
Cost-effectiveness accepted
Decision context
Populationwomen where oral treatments have been ineffective or are contraindicated
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2007 | Recommended · restricted | hysterectomy | — | RCT |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to menorrhagia cases where oral medical therapies have been ineffective or contraindicated; TGA label permits broader use.